Clinical Trial Update: A Study of the Efficacy and Safety of Trastuzumab Emtansine (Trastuzumab-MCC-DM1) vs. Trastuzumab (Herceptin®) and Docetaxel (Taxotere®) in Patients With Metastatic HER2-positive Breast Cancer Who Have Not Received Prior Chemotherapy for Metastatic Disease [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the efficacy and safety of Trastuzumab emtansine (T-DM1) versus Trastuzumab plus Docetaxel in metastatic HER2-positive breast cancer …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• HERCEPTIN (trastuzumab)
• Kadcyla (ado-trastuzumab emtansine)
• Taxotere (docetaxel)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2013-05-20